Bayer announces that its innovative therapy Kerendia™ (finerenone) has received approval in India for the treatment of adult patients with heart failure with a preserved and mildly reduced ejection fraction (HFpEF/HFmrEF).

This expands finerenone’s existing approval in India, received in 2022, for chronic kidney disease (CKD) associated with type 2 diabetes (T2D), where it has already been proven to slow kidney disease progression and reduce cardiovascular (CV) risk.

Shweta Rai, Managing Director – India and Country Division Head – South Asia, Bayer’s Pharmaceutical Division , said, “Our focus is on bringing breakthrough therapies to Indian patients faster, in areas where the unmet medical need is the greatest. With the expansion of finerenone’s indication, we are addressing types of he

See Full Page